Skip to main content
. 2019 Sep 5;5(11):1582–1588. doi: 10.1001/jamaoncol.2019.2792

Figure 2. Overall and Progression-Free Survival.

Figure 2.

A, The median overall survival was 9.3 months in patients treated with doxorubicin plus sorafenib compared with 9.4 months among those treated with sorafenib alone. B, The median progression-free survival was 4.0 months among patients treated with doxorubicin plus sorafenib compared with 3.7 months among those treated with sorafenib alone.